Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections

Pediatric Infectious Disease Journal · Published 2026-07-04 · DOI 10.1097/inf.0000000000005323

Free full text

Authors (19)

John S. Bradley, Carmelle T. Norice, Emmanuel Roilides, Alexey Shevelev, Beata Jurkiewicz, Jorge A. Piedrahita, Mercedes Macías-Parra, Victor Antonio Monroy Colin, Nazan Dalgic, Sandra Koseoglu, Ireen Masih, Prachi Nair, Katherine Young, David W. Hilbert, Garrett T. Nieddu, Munjal Patel, Jennifer A. Huntington, Amanda Paschke, Christopher J. Bruno

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Bradley, J., Norice, C., Roilides, E., et al. (2026). Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections. Pediatric Infectious Disease Journal. https://doi.org/10.1097/inf.0000000000005323

Related articles